Jian Irish sold $2,479 of MGX
See Remarks at Metagenomi Therapeutics, Inc.. 2,140 shares at an average of $1.16, traded Sep 8, 2026, filed Sep 10, 2026.
Score components
- +15RoleOfficer
- 0Trade size$2k at market
- 0Share of holdings soldSold 0.6% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-387798, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | SOpen-market sale Common Stock | -2,140 | $1.16 | $2,479 | 375,393 | 32 d ago |
Related signals
Other insiders at Metagenomi Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | MGXbuy Metagenomi Therapeutics, Inc. | Laurence Reid director | $23k 20,000 shares | - | |
| 37Weak | Metagenomi Therapeutics, Inc. | Pamela Wapnick Chief Financial Officer | $2,214 1,911 shares | -1% | |
| 30Weak | Metagenomi Therapeutics, Inc. | Matthew Wein See Remarks | $415 358 shares | -0% | |
| 40Moderate | Metagenomi Therapeutics, Inc. | Jian Irish Chief Executive Officer | $2,571 1,607 shares | -0% | |
| 30Weak | Metagenomi Therapeutics, Inc. | Matthew Wein See Remarks | $771 482 shares | -0% | |
| 37Weak | Metagenomi Therapeutics, Inc. | Pamela Wapnick Chief Financial Officer | $2,530 1,581 shares | -1% | |
| 40Moderate | Metagenomi Therapeutics, Inc. | Jian Irish Chief Executive Officer | $2,839 1,602 shares | -0% | |
| 37Weak | Metagenomi Therapeutics, Inc. | Pamela Wapnick Chief Financial Officer | $2,793 1,576 shares | -1% | |
| 30Weak | Metagenomi Therapeutics, Inc. | Matthew Wein See Remarks | $353 199 shares | -0% | |
| 30Weak | Metagenomi Therapeutics, Inc. | Brian C. Thomas Chief Executive Officer | $6,786 3,830 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.